

REMARKS

These remarks are in response to the Office Action mailed March 18, 2004. The specification has been amended to comply with the sequence listing requirements. Claims 8-9 have been canceled without prejudice to Applicants' right to prosecute the canceled subject matter in any divisional, continuation, continuation-in-part, or other application. Claims 1 and 10 have been amended. Claim 12 has been added. Support for the amendments and the new claim can be found throughout the specification and claims as originally filed. For example, new claim 12 is supported in canceled claims 8-9. Accordingly, no new matter is believed to have been introduced.

I. SEQUENCE LISTING REQUIREMENT

Accompanying this response is a paper copy and computer readable copy of the sequence listing.

II. REJECTION UNDER 35 U.S.C. §112, FIRST PARAGRAPH

Claims 1-5 and 8-11 stand rejected under 35 U.S.C. §112, first paragraph as allegedly containing subject matter which was not described in the specification in such a way as to reasonably convey to one of skill in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Applicants respectfully traverse this rejection with respect to the claims presented herein.

Claims 1 and 10 have been amended. Applicants submit that the amendments to the claims overcome the Examiner's rejection. Accordingly, the rejection may be withdrawn.

Claims 8-9 stand rejected under 35 U.S.C. §112, first paragraph as allegedly containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains or with which it is most nearly connected to make and/or use the invention. Claims 8-9 have been canceled without prejudice, thus the rejection is moot with respect to these claims. Applicants respectfully traverse this rejection.

Applicants respectfully submit that the term "pharmaceutical composition" is followed by the transitional phrase "comprising" which recites the elements present in such a composition. Applicants submit that the term "pharmaceutical composition" is used in the medical and research fields to include substances that are pharmaceutically acceptable for use in cell cultures, for example.

New claim 12 reflects the language suggested by the Examiner at page 5 of the Office Action.

Accordingly, Applicants respectfully request withdrawal of this §112, first paragraph rejection.

III. REJECTION UNDER 35 U.S.C. §112, SECOND PARAGRAPH


Claims 8-10 stand rejected under 35 U.S.C. §112, second paragraph as allegedly indefinite for failing to particularly point out and distinctly claim the subject matter which applicants regard as the invention. Claims 8 and 9 have been canceled without prejudice, thus the rejection is moot with respect to these claims. Claim 10 has been amended to more clearly set forth Applicants' invention. The rejection may be properly withdrawn.

Please apply any other charges or credits to deposit account 06-1050.

Respectfully submitted,

Date: _____

6/17/04



Joseph R. Baker, Jr.
Reg. No. 40,900

Fish & Richardson P.C.
PTO CUSTOMER NO. 20985
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-5070
Facsimile: (858) 678-5099